Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | IDE | P14735 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HLCS | P50747 | 6/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165464 | 1.00 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL140972 | 1.00 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31224941 | 1.00 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10002269 | 0.91 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1727527 | 0.91 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13888577 | 0.91 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14922108 | 0.90 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14922112 | 0.90 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3870139 | 0.89 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10088098 | 0.85 | TDP1 (0.59) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527846-B2 | Immunodominant proteins and fragments in multiple sclerosis | Universität Zürich (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20250332229-A1 | IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | Universität Zürich (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4640282-A2 | IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | Universität Zürich (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-20250276058-A1 | NANOFIBERS TO PRIME ANTIBODY RESPONSES AND METHODS OF USING SAME | UNIV DUKE (US) | 2025-09-04 | — | — | US | disclosed |
| EP-3813865-B1 | IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | UNIV ZUERICH (CH) | 2025-08-06 | — | — | EP | disclosed |
| US-20250161413-A1 | METHODS FOR DECREASING PATHOLOGIC ALPHA-SYNUCLEIN USING AGENTS THAT MODULATE FNDC5 OR BIOLOGICALLY ACTIVE FRAGMENTS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119971002-A | Immunodominant proteins and fragments in multiple sclerosis | 苏黎世大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025050032-A1 | METHODS OF PRODUCING CDKL5 PROTEINS AND USES OF THE SAME | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119555930-A | Photo-activated chemiluminescence detection reagent composition, kit, detection method and device | 科美诊断技术股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250035643-A1 | UNBIASED AND HIGH-THROUGHPUT IDENTIFICATION AND QUANTIFICATION OF HOST CELL PROTEIN IMPURITIES BY AUTOMATED ITERATIVE LC-MS/MS (HCP-AIMS) FOR THERAPEUTIC PROTEIN DEVELOPMENT | REGENERON PHARMACEUTICALS, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2010012949-A1 | MARKER REAGENTS WITH A PYRIDINE RING WITH A DIAZOMETHYL FUNCTION SUBSTITUENT METHODS FOR SYNTHESIS OF SAID REAGENTS AND METHODS FOR DETECTING BIOLOGICAL MOLECULES | BIOMERIEUX (FR) | 2010-02-04 | — | — | WO | disclosed |
| US-20100015717-A1 | Mass Tags for Quantitive Analysis | PPD BIOMARKER DISCOVERY SCIENCES LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-7544518-B2 | Rapid quantitative analysis of proteins or protein function in complex mixtures | UNIVERSITY OF WASHINGTON (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544518-B2 | Rapid quantitative analysis of proteins or protein function in complex mixtures | UNIVERSITY OF WASHINGTON (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090124562-A1 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent | TOUDAI TLO, LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124562-A1 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent | TOUDAI TLO, LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090010845-A1 | Polybiotin Compounds of Magnetic Resonance Imaging and Drug Delivery | THE GENERAL HOSPITAL CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090010845-A1 | Polybiotin Compounds of Magnetic Resonance Imaging and Drug Delivery | THE GENERAL HOSPITAL CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7438893-B2 | Polybiotin compounds for magnetic resonance imaging and drug delivery | MASSACHUSETTS GENERAL HOSPITAL (US) | 2008-10-21 | — | — | US | disclosed |
| US-7438893-B2 | Polybiotin compounds for magnetic resonance imaging and drug delivery | MASSACHUSETTS GENERAL HOSPITAL (US) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124562-A1 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent | HSPA4, GRPR, HSPA5 | TDP1 2286/4885MEN1 3102/4885ABL1 3972/4885 |
| US-20090010845-A1 | Polybiotin Compounds of Magnetic Resonance Imaging and Drug Delivery | BTD, BCAT1, BRD4 | TDP1 3576/4885MEN1 336/4885ABL1 1751/4885 |
| US-12527846-B2 | Immunodominant proteins and fragments in multiple sclerosis | MAG, GMFG, FUCA1 | TDP1 3712/4885MEN1 2787/4885ABL1 3936/4885 |
| US-20100015717-A1 | Mass Tags for Quantitive Analysis | PTMS, CHAMP1, TMT1A | TDP1 2376/4885MEN1 3442/4885ABL1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.